Neuropsychological and biomedical assessment of depression-dementia syndromes

Stoudemire, Alan; Hill, Connie; Gulley, Lawrence R.; Morris, Robin

doi:10.1176/jnp.1.4.347

Cited by 29 publications

(1 citation statement)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the type and extent of cognitive dysfunction is important in assessing the course of treatment. Attending physicians can evaluate functional impairment for their patients, and neuropsychological testing can be performed in the hospital 17 . However, it is difficult for the attending physician to intervene if the treatment is interrupted.…”

Section: Introductionmentioning

confidence: 99%

Work functioning impairment in the course of pharmacotherapy treatment for depression

Nagata

Fujino

Ohtani

et al. 2020

Sci Rep

View full text Add to dashboard Cite

This study investigated the association between the duration of pharmacotherapy treatment for depression, or discontinuation from treatment, and work functioning impairment. This was a retrospective cohort study examining 30,409 workers. Work functioning impairment was assessed using a questionnaire, and treatment status was assessed using medical claims data. Odds ratios (ORs) of workers with severe work functioning impairment compared with healthy workers (control group) were calculated using logistic regression analysis. Continuous medical treatment was associated with severely impaired work functioning regardless of treatment period [continuous medical treatment; 4 months <: OR = 3.2, 4 months ≥, 10 months <: OR = 2.6, 10 months ≥, 14 months <: OR = 2.3, 14 months ≥, 16 months <: OR = 2.3, which are all statistically significant (p < 0.05)]. Workers who initially received pharmacotherapy treatment but discontinued in < 11 months had a significantly higher OR (treatment discontinuation period; 3 months <: OR = 2.3, 3 months ≥, 8 months <; OR = 2.0, 8 months ≥, 11 months <; OR = 3.0), while those who discontinued at ≥ 11 months did not (OR = 1.4, 95% CI 0.6–3.5). The sensitivity analysis excluding participants with at least one psychiatric comorbidity other than depression did not change the final result. It is important for the occupational health practitioners and attending psychiatrists to follow up in cooperation with each other, paying attention to the decrease in work functioning in addition to the symptoms.

show abstract

Section: Introductionmentioning

confidence: 99%

Work functioning impairment in the course of pharmacotherapy treatment for depression

Nagata

Fujino

Ohtani

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

The contribution of hypercortisolaemia to the cognitive decline of geriatric depression

Mitchell

1995

Int J Geriat Psychiatry

View full text Add to dashboard Cite

SUMMARYCognitive impairment in depression is well recognized but poorly understood. A subset of depressed patients exhibit a syndrome of severe neuropsychological deficits which may be partially reversible upon episode resolution. This has been called depressive pseudodementia, the dementia syndrome of depression and depression induced cognitive impairment. The epidemiology, clinical features, natural history and prognosis of this condition support the notion of an underlying organic aetiology. The most plausible neurobiological candidate involved in the pathogenesis is hyperactivity of the hypothalamo-pituitary-adrenal (HPA) axis. The homeostatic regulation of the HPA axis becomes increasingly vulnerable to disruption in geriatric depression and perhaps particularly in depressive dementia. Hypercortisolaemia has been correlated with cognitive impairment in depression as well as in other related psychiatric conditions. The mechanism of this abnormality may involve hippocampal dysfunction. Further longitudinal studies are needed to clarify the role of the HPA axis in the cognitive decline of depressive illness.

show abstract

Aging

Nussbaum¹

1995

Handbook of Health and Rehabilitation Psychology

View full text Add to dashboard Cite

Neuropsychological and biomedical assessment of depression-dementia syndromes

Cited by 29 publications

References 98 publications

Work functioning impairment in the course of pharmacotherapy treatment for depression

Work functioning impairment in the course of pharmacotherapy treatment for depression

The contribution of hypercortisolaemia to the cognitive decline of geriatric depression

Aging

Contact Info

Product

Resources

About